Trial Profile
Phase II Study of Everolimus (RAD001, Afinitor(R)) for Children With Recurrent or Progressive Ependymoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Ependymoma
- Focus Therapeutic Use
- 29 Oct 2022 Planned End Date changed from 30 Jul 2022 to 30 Jul 2023.
- 29 Oct 2022 Planned primary completion date changed from 30 Jul 2022 to 30 Jul 2023.
- 31 Jan 2022 Planned End Date changed from 30 Dec 2021 to 30 Jul 2022.